According to one federal analysis, taxpayers may have overpaid for Mylan's EpiPen by as much as $1.27 billion over 10 years as a result of its misclassification. (Photo: Shutterstock)
Senators Ron Wyden, D-Oregon, and Chuck Grassley, R-Iowa, have introduced a bill that's aimed at the methods drug companies use to overcharge taxpayers for Medicaid rebates.
As The Hill reports, the bill, put forward by the incoming chairman and ranking member of the Senate Finance Committee, could mean that the two are looking for common ground on drug prices.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Marlene Satter
Marlene Y. Satter has worked in and written about the financial industry for decades.
